Can Medication Treat a Child's Sleep Apnea Instead of Surgery?

If a child has obstructive sleep apnea from enlarged tonsils and adenoids, the standard treatment is surgical. Understandably, most parents want to know whether a medicine could do it instead.

The answer depends entirely on what you mean by "do it," and the published evidence looks contradictory until you notice that the two halves are measuring different things.

What the drug evidence says

A 2025 systematic review searched three databases for randomised trials of intranasal corticosteroids and oral montelukast in otherwise healthy children with sleep-disordered breathing and adenoid hypertrophy.

Its conclusion is positive. Intranasal corticosteroids — mometasone, beclometasone, budesonide, fluticasone, flunisolide — consistently produced clinical and instrumental improvement in adenoid hypertrophy and related respiratory symptoms, with a generally favourable safety profile. Combining montelukast with an intranasal steroid appeared better than either alone. The review concludes both classes effectively and safely manage adenoid hypertrophy and mild-to-moderate OSA symptoms in children.

It is also candid about its limits: the studies varied widely in dosage, duration, design and sample size, and long-term safety data in children are lacking.

What the trial evidence says

Now the other half. A randomised, double-blind, placebo-controlled trial published in Chest in 2022 gave 134 children aged 5 to 12 with obstructive sleep apnea syndrome three months of intranasal corticosteroids or placebo, then re-randomised the treatment arm for a further nine months.

The obstructive apnea-hypopnea index did not differ significantly from placebo. Change at three months was −1.72 events per hour and at twelve months −1.2, neither separating from placebo. The authors noted that these drugs are frequently used for this purpose and that their efficacy had not been rigorously tested.

Why both are correct

The review's outcomes are adenoid size and respiratory symptoms. The trial's primary outcome was the apnea-hypopnea index.

Those are not the same target, and the honest synthesis is that these drugs shrink adenoidal tissue and make children less symptomatic, while the best-controlled test of whether they fix the apnea itself came back negative.

That distinction is exactly the one that matters for a surgical decision. If your child's problem is nasal obstruction, mouth breathing and disturbed nights, medical management has a real chance of helping. If your child has measured obstructive sleep apnea and the question is whether a spray will normalise it, the controlled evidence says do not count on it. It also reinforces what the same drugs do and do not do in adults.

Evidence tier 1 that intranasal corticosteroids reduce adenoid hypertrophy and symptoms. Tier 3 for normalising a child's apnea index, where the one rigorous placebo-controlled trial found no effect.

The montelukast warning parents should hear first

This is the part most likely to be left out of a hopeful conversation about avoiding surgery.

Montelukast carries a US boxed warning for serious neuropsychiatric events, added by the FDA in 2020 — including agitation, depression, sleep disturbance and suicidal thinking and behaviour. A 2025 JAMA Pediatrics study examined neuropsychiatric adverse events in children taking it, and prescribing patterns changed measurably after the warning.

None of that makes montelukast unusable — it remains a legitimate prescription and most children take it without trouble. It does mean the systematic review's summary that side effects are "mostly mild" is not the whole picture for this particular drug, and that a parent weighing it against an operation deserves both facts. The conversation belongs with the prescribing clinician, and any change in mood, sleep or behaviour after starting it is worth reporting promptly.

The practical version

Medical management is a reasonable first step for mild disease. No desaturation, no significant daytime impact, symptoms mainly nasal — then a trial of an intranasal steroid, given the full six to eight weeks rather than a few days, is defensible and low-risk.

It is not a substitute for assessment. A sleep study establishes severity, and severity is what decides whether watchful waiting, medication or surgery is appropriate.

Remember that many children resolve without anything. In the main surgical trial, 46% of children who had no treatment at all had normal sleep studies seven months later. Improvement on a drug is not proof the drug did it. What the adenotonsillectomy trial actually found.

For moderate-to-severe apnea, do not use medication to delay a decision. Months of spray while a child sleeps badly is months lost, and the surgical evidence for behaviour, quality of life and the apnea itself is considerably stronger than the drug evidence.

And nothing sold for adult snoring applies to a child. No nasal strip, mouth tape or positional device is a treatment for paediatric obstructive sleep apnea. Why children and nasal strips are a different question.

The signs that warrant prompt assessment rather than a trial of anything: witnessed pauses in breathing, gasping or choking, laboured breathing or chest retraction during sleep, sleeping with the neck extended, persistent mouth breathing, bedwetting that restarts, and daytime hyperactivity or behaviour problems — children with apnea present as hyperactive more often than sleepy. Snoring versus apnea.